Nasus Pharma is trading up 6.29% at $3.38 on October 19, 2026, amid broader-market strength; no company-specific catalyst has been verified.
- The S&P 500 was up 0.60% and the Nasdaq Composite was up 1.22%, supporting a broader risk-on backdrop.
- The latest company announcement found was about the first patient dosed in a Phase 1 study, dated September 29—not a new October 19 announcement.